Chemomab Therapeutics Ltd.

US$1.32As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:CMMBHealthcare
Country USA
PE (Fwd) •••
TSR 6Y CAGR (54.91%)
Div yield —
ROE (82.17%)
Biotechnology
Beta (5Y) 0.79
PE TTM —
TSR TTM (56.86%)
Mkt cap US$9.564M
ROIC (53.78%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$1.59
20.20%
(85.12%)
Hold 9|11|1|4|1
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.01
0.01
0.01
0.01
(1.41%)
7.29%
7.60%
0.94%
Revenue$M
0.557
0.545
0.543
0.572
(1.55%)
(2.12%)
(2.58%)
4.71%
Peers (US$9.564M)
Cap (US$)
PE
10.13M
—
9.333M
—
Capital
TTM
5Y
10Y
Leveragex
0.225
2.421
2.204
EBIT/Intx
0.387
1.322
1.397
Own earn%
(87.58)
14.37
16.48
Sh yield%
47.79
23.58
21.19
Owners
Insiders/Inst%
7.06
77.47
Short interest%
1.87
SBC / revenue%
4.48
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
17
Op margin range%
10–26
$1 testx
−0.1
Incr. ROIC%
−1